Anna Ferrari

Biosketch / Results /

Anna Ferrari, M.D.

Professor;
Departments of Medicine (Perlmutter Cancer Center) and Medicine (Residency Program)
NYU Medical Oncology Associates

Clinical Addresses

160 E. 34TH STREET, 8TH FLOOR
NEW YORK, NY 10016
Hours: Wed. 8 - 5; Thu. 8 - 5
Handicap Access: yes
Phone: 212-731-5389
Fax: 212-731-5545

« Back to Results

Medical Specialties

Cancer, Medical Oncology

Medical Expertise

Genitourinary Cancer, Bladder Cancer, Metastatic Prostate Cancer, Kidney Cancer, Prostate Cancer, Testicular Cancer, Recurrent Prostate Cancer

Clinical Responsibilities

I am a clinician?scientist with an established translational research record in prostate cancer (PC). My experience includes clinical trial development based on preclinical testing of novel agents and molecular correlates of progression. Examples of my basic-therapeutic, goal-oriented experience are: (1)preclinical and clinical testing of novel drug combinations to simultaneously block either AR ligand activation and histone deacetylases (LBH589/Panobinostat) in order to reverse resistance to hormone therapy (ph I/II NYU-08479 /DOD Consortium/ Novartis) or cross-talk of the AR with PI3/Akt/mTor signaling in order to avoid castration in recurrent PC (ECOG 2809/CTEP). (2)the identification of a repressor of the androgen receptor (AR) linked to overexpression of AR in an androgen-independent LNCaP derivative and castration-resistant PC (CRPC) specimens; and (3) experience in conducting tissue correlative studies interacting with multiple basic and clinical investigators include: (a) R21CA79918-01, a 400-patient international trial of molecular staging of occult micrometastases in pathologically normal lymph nodes as a prognostic indicator of biochemical recurrence; and (b) RO1CA098135-01, a study of the role of KLF6 gene alterations in PC progression. In this study we first observed that KLF6 splicing became diverse and magnified in neo-androgen deprived PC tissues (neoADT) and conferred AI PC growth in vitro. Currently, I am the translational science chair for the ECOG GU Committee, and, in this capacity, I recently designed and recruited expert investigators in next-generation transcriptome and immunohistochemistry analysis for correlative studies for a major Phase III adjuvant hormone therapy trial.

Languages

French, Spanish

Insurance

AETNA HMO, AETNA INDEMNITY, AETNA MEDICARE, AETNA POS, AETNA PPO/EPO, AFFINITY, CIGNA EPO/POS, Cigna PPO, EBCBS EPO, EBCBS HLTHY NY, EBCBS HMO, EBCBS INDEMNITY, EBCBS MEDIBLUE, EBCBS PATHWAYS / PATHWAYS ENHANCED, EBCBS POS, EBCBS PPO, ELDERPLAN, GHI CBP, HEALTHREPUBLIC, HIP ACCESS I, HIP ACCESS II, HIP CHLD HLTH, HIP EPO/PPO, HIP HMO, HIP MEDICARE, HIP POS, LOCAL 1199 PPO, MAGNACARE PPO, METROPLUS CHLD HLTH, METROPLUS EXCHANGE PLANS, METROPLUS FAM HLTH, MULTIPLAN/PHCS PPO, Medicare, MetroPlus Medicaid, NY MEDICAID, NYS EMPIRE PLAN, OSCAR, OXFORD EXCHANGE, OXFORD FREEDOM, Oxford Liberty, Oxford Medicare, Railroad Medicare, Tricare, UHC COMMUNITY & STATE PLAN, UHC EPO, UHC HMO, UHC MEDICARE, UHC POS, UHC PPO, UHC TOP TIER UNITED EXCHANGE- COMPASS, UPN Elite, WELLCARE CHLD HLTH, WELLCARE FAM HLTH, WELLCARE MEDICAID, WELLCARE MEDICARE

Insurance Disclaimer: Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have changed.

« Back to Results

Board Certification

1986 — Ab Internal Medicine - Internal Medicine
1987 — Ab Internal Medicine (Medical Oncology)

Education

1974 — University of Uruguay, Medical Education
1975-1978 — Universidad de la Republica del (Medicine), Residency Training
1980-1982 — National Cancer Institute (Cancer Research), Clinical Fellowships
1982-1985 — Union Memorial Hospital (Medicine), Residency Training
1982-1986 — Bronx Municipal Hospital Center (Hematology), Clinical Fellowships
1986-1988 — New York University Medical Center (Oncology), Clinical Fellowships